In Vivo Target Screening

Traditional target discovery in pharma starts with in-vitro assays. While this approach works for some applications, it does not capture the interactions of age-related diseases. This has limited the success rates of therapeutics for complex diseases.

Arrive has developed a unique system to make in vivo target screening feasible. By combining machine learning, bioinformatics, and a proprietary knowledge database we make in vivo target discovery possible.

Liver

The liver is a major driver of regulating the body’s metabolism, ensuring homeostatic energy balance and regulating immune and even brain activity.  Approximately 1 in 4 adults globally have fatty liver disease (NAFLD) with increasing prevalence with age.  While ageing reduces the liver’s regenerative capacity, this can be resolved through lifestyle choices.¹

Muscle

Muscle strength decreases on average of 10% per decade after age 40. Loss of or reduced mobility with age contributes to nearly 3 million fall injuries among the elderly in the US alone, contributing to nearly $50B in healthcare costs.  Loss of muscle, or sarcopenia, can be delayed or reversed by exercise.²

Brain

11-20% of people over 65 experience subjective cognitive decline resulting in >$300B in healthcare costs per year in the US alone. However some people can improve their symptoms with lifestyle modification, which indicates potential for new preventative therapies.³